Navigation Links
Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs

-Expands PDE10 Collaboration with Amgen-

-Company to Host Conference Call at 9:00 A.M. EDT-

MONTVALE, N.J., March 12 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced that it has realigned its operations, reallocated its resources and extended the preclinical research portion of its PDE10 collaboration with Amgen. The Company will focus its near-term and mid- term efforts on two partnered programs, its nicotinic alpha-7 receptor agonist collaboration with Roche and the PDE10 collaboration with Amgen, and two proprietary programs, its PDE4 inhibitor and 5-HT6 antagonist programs.

"After conducting a thorough review of our pipeline, opportunities and financial resources, we have decided to focus on those areas where we can most optimally apply our expertise to create significant clinical and shareholder value," stated Vaughn M. Kailian, President and Chief Executive Officer of Memory Pharmaceuticals. "Consequently, we have reduced our discovery research effort in favor of progressing our four major programs."

In connection with this new operational focus, the Company implemented the following initiatives.
-- Reallocation of Resources. Memory Pharmaceuticals has realigned its

workforce to support its key development and clinical programs. The

Company has reduced its overall efforts dedicated to discovery

research, while maintaining its capabilities in CNS drug discovery to

support long-term growth. The Company's overall headcount has been

reduced by 20% and the Company has shifted its resources toward

development activities. The new structure will support the Company's

preclinical and clinical activities and business development


-- Focus on Key Development Activities. The Company plans to dedicate the

majority of its resources and investments to support continued

development of key partnered and proprietary programs:

-- Nicotinic Alpha-7 Receptor Agonist Collaboration with Roche. MEM

3454, the lead compound in the Company's nicotinic alpha-7 receptor

agonist collaboration with Roche, demonstrated a statistically

significant effect on multiple measures of cognition in a recent

Phase 2a study in Alzheimer's disease. Memory Pharmaceuticals is

currently evaluating the compound as a treatment for cognitive

impairment associated with schizophrenia (CIAS) in a Phase 2a trial

and expects to report top-line data from that trial in the fourth

quarter of 2008. In addition, the Company expects to initiate a

biomarker study for MEM 3454 in schizophrenia this summer, with

results expected by early 2009. The biomarker study will be funded

by Roche.

-- Memory Pharmaceuticals also expects to complete its Phase 1 program

for MEM 63908 and report top-line results in the fourth quarter of


-- PDE10 Inhibitor Collaboration with Amgen. The Company has amended

its collaboration with Amgen focused on the development of PDE10

inhibitors for certain neurological and psychiatric disorders.

Memory Pharmaceuticals has agreed to commit and fund certain

preclinical research resources and provide increased access to its

screening technologies to the collaboration over the next twelve

months. In exchange, Memory Pharmaceuticals will receive increased

milestone payments upon the achievement of certain predefined

development events for the program. In addition, the parties

expanded the scope of compounds eligible for higher tier royalties

under the agreement.

-- PDE4 Inhibitor Program. The Company's PDE4 inhibitor program

includes MEM 1414, along with MEM 1917 and several backup compounds.

The Company believes that PDE4 inhibitors could be beneficial in

treating a number of cognition-related CNS disorders and

inflammatory diseases. MEM 1414 has demonstrated efficacy in a

broad range of preclinical cognition and anti-inflammatory models.

In addition, Phase 1 studies have demonstrated a favorable safety

profile for the compound overall and particularly with respect to

nausea and vomiting, which has limited the development of other PDE4

compounds. The Company plans to progress MEM 1414 into a Phase 2a

trial by the end of 2008.

-- 5-HT6 Antagonist Program. 5-HT6 antagonists are potential

treatments for Alzheimer's disease, schizophrenia, attention deficit

disorder and obesity. Memory Pharmaceuticals has generated a

portfolio of novel, potent and selective 5-HT6 antagonists and is

evaluating several lead compounds as potential development

candidates. The Company plans to advance the program into clinical

trials by the end of 2008.

Conference Call and Webcast Information

Memory Pharmaceuticals will hold a conference call today, March 12, 2008, at 9:00 a.m. EDT to discuss the new operational focus. The conference call will also be broadcast live from the "Investors" section of the Company's website. Memory Pharmaceuticals' senior management will host the conference call. Investors and other interested parties may access the call as follows:

Date: Wednesday, March 12, 2008

Time: 9:00 a.m. EDT

Telephone (U.S.): 866.356.4279

Telephone (international): 617.597.5394

Participant Passcode: 69644115


under the "Investors" section

An audio replay of the conference call will be available from 11:00 a.m. EDT on Wednesday, March 12, 2008, until Wednesday, March 19, 2008. To access the replay, please dial 888.286.8010 (U.S.) or 617.801.6888 (international) and enter passcode number 18675332. An audio replay of the conference call will also be available under the "Investors" section of the Company's website during the same period.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia. For additional information, please visit our website at

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or Memory Pharmaceuticals' prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the outcome of clinical trials of Memory Pharmaceuticals' drug candidates and whether they demonstrate these candidates' safety and effectiveness; the risks and uncertainties associated with: obtaining additional financing to support Memory Pharmaceuticals' R&D and clinical activities and operations; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals' dependence on its collaborations and its license relationships; achieving milestones under Memory Pharmaceuticals' collaborations; Memory Pharmaceuticals' dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; protecting the intellectual property developed by or licensed to Memory Pharmaceuticals; and Memory Pharmaceuticals' ability to maintain listing on the Nasdaq Global Market. These and other risks are described in greater detail in Memory Pharmaceuticals' filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Memory Pharmaceuticals disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
2. Scientists synthesize memory in yeast cells
3. Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster
4. Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster
5. Scientists synthesize memory in yeast cells
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. BioMedical Enterprises, Inc. (BME) Receives FDA Clearance for Spine Use of Its Memory Metal Implants
8. ASU researchers improve memory devices using nanotech
9. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
10. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
11. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
Post Your Comments:
(Date:10/11/2017)... ... ... a basic first aid supply for any work environment, but most personal eye wash can ... a dangerous substance enters both eyes? It’s one less decision, and likely quicker response time ... , “Whether its dirt and debris, or an acid or alkali, getting anything in your ...
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
(Date:10/11/2017)... Austin, TX (PRWEB) , ... October 11, 2017 ... ... in August compared the implantation and pregnancy rates in frozen and fresh ... the contribution of progesterone and maternal age to IVF success. , After comparing ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
Breaking Biology Technology:
(Date:10/4/2017)... , Oct. 4, 2017  GCE Solutions, a global clinical ... data and document anonymization solution on October 4, 2017. Shadow is ... field to comply with policy 0070 of the European Medicines Agency ... data. ... GCE Solutions ...
(Date:7/20/2017)... Delta (NYSE: DAL ) customers now can use ... Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington ... Delta,s biometric boarding pass experience that ... integrated into the boarding process to allow eligible Delta SkyMiles Members who ...
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
Breaking Biology News(10 mins):